Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply.

Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply.

Bibliographic Details
Main Authors:	Reenaers, C, Louis, E, Belaiche, J, Seidel, L, Keshav, S, Travis, S
Format:	Journal article
Language:	English
Published:	2013

Similar Items

Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?
by: Reenaers, C, et al.
Published: (2012)

Adalimumab induction therapy achieves clinical remission and response in Chinese patients with Crohn's disease
by: Wu, K, et al.
Published: (2015)

Immunosuppression for management of Crohn's disease
by: Milosevic, I, et al.
Published: (2016)

Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
by: Wu, K, et al.
Published: (2016)

Editorial: gut selective immunosuppression-is it a double edged sword? Authors' reply.
by: Bye, W, et al.
Published: (2017)

Authors' reply to letter [6]
by: Aveyard, P, et al.
Published: (2007)

Letter to the editor and authors' reply
by: Baerns, M, et al.
Published: (1990)

Medical management of Crohn's disease.
by: Cummings, JR, et al.
Published: (2008)

PACE trial authors' reply to letter by Kindlon.
by: White, P, et al.
Published: (2013)

Managing smoking cessation Authors’ reply to letter
by: Aveyard, P, et al.
Published: (2007)

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
by: Panaccione, R, et al.
Published: (2019)

Authors' reply: The association between visceral adipose tissue and stricturing crohn's disease behavior, fecal calprotectin and quality of life
by: Bryant, R, et al.
Published: (2018)

Has primary sclerosing cholangitis associated with Crohn's disease a better outcome? Reply
by: Halliday, J, et al.
Published: (2012)

Reply to Dr. Ngu et al.'s letter
by: Halliday, J, et al.
Published: (2012)

Lymphoma risk and overall safety profile of Adalimumab in patients with Crohn's disease with up to 6 years of follow-up in the pyramid
by: D'Haens, G, et al.
Published: (2018)

Blood pressure treatment: how low should you go? – Authors' reply
by: Rahimi, K, et al.
Published: (2021)

Does it all ADA up? Adalimumab for ulcerative colitis.
by: Travis, S
Published: (2011)

This is not the EAT– Lancet Diet – Authors' reply
by: Papier, K, et al.
Published: (2020)

Tamoxifen therapy for patients with breast cancer - Authors' reply.
by: Davies, C, et al.
Published: (2013)

Letter of reply
by: Bennett, G, et al.
Published: (2015)

Authors' reply
by: Herbert, K, et al.
Published: (2012)

Authors' reply
by: Khan, A, et al.
Published: (2010)

Authors' reply
by: Leucht, S, et al.
Published: (2013)

The authors reply
by: Holman, R, et al.
Published: (2009)

The authors reply
by: Rahman, N, et al.
Published: (2011)

The authors' reply
by: Hobbs, F, et al.
Published: (2011)

The authors reply
by: Burdmann, E, et al.
Published: (2017)

Authors' reply
by: White, P, et al.
Published: (2011)

The authors reply
by: Collins, R, et al.
Published: (2009)

Authors' reply.
by: Garety, P, et al.
Published: (2014)

The authors reply
by: Holman, R, et al.
Published: (2008)

The authors reply
by: Kheifets, L, et al.
Published: (2011)

Authors' reply
by: Aiken, A, et al.
Published: (2012)

The authors reply.
by: Schlüssel, M, et al.
Published: (2013)

Authors' reply
by: Davies, H, et al.
Published: (2009)

Authors' reply
by: Aveyard, P, et al.
Published: (2008)

Authors' reply
by: Seymour, M, et al.
Published: (2011)

The authors reply
by: Farrall, M, et al.
Published: (2010)

The authors reply
by: Holman, R, et al.
Published: (2010)

The authors reply
by: Moers, C, et al.
Published: (2009)